🇺🇸 FDA
Patent

US 11446360

High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same

granted A61KA61K38/28A61K9/0073

Quick answer

US patent 11446360 (High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same) held by Amphastar Pharmaceuticals, Inc. expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Amphastar Pharmaceuticals, Inc.
Grant date
Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K38/28, A61K9/0073, A61K9/008, A61K9/143